Farmers, Founders and Financiers Forum: AgTech’s Search for a Path Forward

The Glynwood Center for Regional Food and Farming, Byrne Advisory, and Interior Lines Advisory recently hosted a one-day forum in the Hudson Valley to address the malaise currently affecting the AgTech sector. The event brought together a diverse assembly of leaders from agriculture, start-ups, and the investment community (including Wall Street) to address the financing and business model challenges confronting the industry. The setting was Glynwood Farm.

A Bearish Backdrop

Sentiment remains decidedly bearish regarding the market backdrop for capital increases and exits through 2026. Venture Capital investment has retreated significantly from the 2021 peak.

AGTech Venture Capital Investment

Source: Pitchbook

Investors do not expect a return to 2021 investment levels in the near future. With capital becoming increasingly scarce, competition among thousands of aspiring start-ups across various AgTech sectors is fierce.

Despite these financial headwinds, optimism persists regarding the fundamental need for AgTech to improve yields and reduce inputs for farmers, particularly in the specialty crop area. Reaching this potential, however, requires navigating a thicket of technological, regulatory, and capital hurdles.

The Frontier of Gene Editing and Biologicals

The forum identified Gene Editing and Biologicals as two areas of significant scientific promise, though both face distinct commercial obstacles.

Gene Editing

Participants agreed on the potential to increase crop yields through Gene Editing. The discussions focused on the ability to use this technology to accelerate yield gains in row crops and to develop consumer-friendly traits in specialty crops. While row crops remain a focus, there is a significant opportunity in specialty crops where seed germplasm is not yet optimized.

However, Gene Editing start-ups face challenges in accessing high-quality germplasm and often lack the institutional knowledge required to partner effectively with the large, dominant seed companies that control these resources.

Biologicals

As with Gene Editing, several participants highlighted that specialty crops may offer a clearer path toward commercialization for Biologicals versus row crops due to the significantly higher value per acre and less influence by crop input distributors in farmer decisions. Several speakers held the view that the consolidated distribution channels in the U.S. have been an obstacle for Biologicals adoption by farmers.

Additionally, South America—particularly Brazil—may represent a major opportunity due to weathered soils that benefit from plant-health enhancers and less consolidated distribution channels that allow for direct sales to growers.

A more detailed summary of the scientific issues underlying the potential of Gene Editing and Biologicals is available in the Byrne Advisory Substack posting.

The Changing Face of Wall Street

The role of Wall Street in the start-up space is evolving rapidly. Traditional research firms are increasingly adding start-up coverage to their public company work to meet high demand; one participant noted that readership for Start-up reports was three times higher than for their public company research.

This shift provides start-ups with an incremental pool of capital and new investment partners. Furthermore, FinTech companies are developing new vehicles to provide advisory services and capital-raising solutions, including platforms that allow retail investors to participate in start-up investments.

Summary

While the AgTech sector faces significant hurdles in capital availability and commercialization, the progress in Gene Editing and Biologicals—combined with the expanding support from Wall Street—offers a viable path forward.